Unlocking Scale: Rethinking Tools for the Next Era of Cell and Gene Therapy

As the field of advanced therapies matures, one barrier remains constant: access. Whether autologous or allogeneic, developers need reliable access to high-quality starting material, as well as downstream support for testing, manufacturing, and logistics, along with a scalable model to support clinical growth and commercialization.
At BBG Advanced Therapies, we’ve built infrastructure to serve both. From cord blood and tissue to adipose to leukopaks, our integrated sourcing, testing and processing model is designed for scalability. With demand for donors in cell-based and tissue-derived therapies accelerating, supply and informed consent strategies must evolve with it. We're one of the few, if not only, organizations adapted perfectly for this future.
We’re also helping developers control cost and improve efficiency. Our Mobile Leukapheresis Center removes geographic constraints, and Releasate—our cell-free lysate alternative—is being introduced to support innovation in biomanufacturing and performance and consistency in cell therapies. Together, these are examples of efforts we're working with our partners in an aim to expand access, improve affordability, and make these therapies more feasible for patients everywhere.